Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
JPEN J Parenter Enteral Nutr ; 43(2): 220-225, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30334261

RESUMO

BACKGROUND: Lactate production is exacerbated by surgical stress. We sought to determine whether branched-chain amino acid (BCAA) supplementation could decrease blood lactate levels in patients undergoing hepatectomy. METHODS: A total of 275 consecutive patients who underwent hepatectomy of ≥2 segments were retrospectively reviewed. Blood lactate levels in patients treated with BCAA supplementation before hepatectomy (December 2011 to December 2016) were compared with levels in patients who were not pretreated (January 2008 to November 2011). RESULTS: Postoperative lactate levels were significantly lower in patients who received preoperative BCAA supplementation than in those who did not (2.6 vs 3.4 mmol/L; P < .001). Intraoperative blood lactate levels, which were evaluated after induction of general anesthesia, were also lower in those who received BCAA supplementation than in those who did not (1.1 vs 1.5 mmol/L, respectively; P < .001). A multiple regression analysis revealed that preoperative BCAA supplementation was independently associated with decreased postoperative and intraoperative lactate levels (P = .030 and P < .001, respectively). CONCLUSION: Preoperative BCAA supplementation decreased intraoperative and postoperative blood lactate levels in patients undergoing major hepatectomy.


Assuntos
Aminoácidos de Cadeia Ramificada/farmacologia , Suplementos Nutricionais , Hepatectomia , Ácido Láctico/sangue , Cuidados Pré-Operatórios/métodos , Administração Oral , Aminoácidos de Cadeia Ramificada/administração & dosagem , Aminoácidos de Cadeia Ramificada/sangue , Estudos de Coortes , Feminino , Humanos , Período Intraoperatório , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Estudos Retrospectivos
2.
Pancreas ; 25(1): 45-8, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12131770

RESUMO

INTRODUCTION: The consumption of green tea is associated with a lower risk of several types of human carcinomas. A number of studies have focused on the possible mechanisms of cancer prevention by tea extracts, especially polyphenols such as epigallocatechin-3-gallate (EGCG). AIMS AND METHODOLOGY: Green tea-derived EGCG was tested in human pancreatic carcinoma cells. The cells (PANC-1, MIA PaCa-2, and BxPC-3) were treated with different doses of EGCG (0, 25, 50, 100, and 200 micromol/L) for 48 hours in culture medium. Proliferation of pancreatic carcinoma cells was measured by means of the WST-1 colorimetric assay. For the study of cell invasion, the cells were incubated with 100 micromol/L EGCG for 2 hours. Then, the cells were added into the cell insert, coated with Matrigel basement membrane matrix. After incubation at 37 degrees C for 24 hours, the cells that had invaded through the Matrigel were counted visually under the microscope. RESULTS: The growth of all three pancreatic carcinoma cells was significantly suppressed by EGCG treatment in a dose-dependent manner. EGCG treatment caused significant suppression of the invasive ability of pancreatic carcinoma cells PANC-1, MIA PaCa-2, and BxPC-3 but did not affect the cell cycle protein cyclin D1. CONCLUSION: EGCG may be a potent biologic inhibitor of human pancreatic carcinomas, reducing their proliferative and invasive activities.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Carcinoma , Catequina/análogos & derivados , Catequina/farmacologia , Neoplasias Pancreáticas , Materiais Biocompatíveis , Divisão Celular/efeitos dos fármacos , Colágeno , Ciclina D1/análise , Combinação de Medicamentos , Humanos , Laminina , Invasividade Neoplásica , Proteoglicanas , Chá , Células Tumorais Cultivadas/química , Células Tumorais Cultivadas/citologia , Células Tumorais Cultivadas/efeitos dos fármacos
3.
Hepatogastroenterology ; 49(46): 928-31, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12143244

RESUMO

BACKGROUND/AIMS: It is reported that polyphenol is associated with low risk of hepatoma and that RAGE (receptor for advanced glycation end products) is important for cancer invasion. METHODOLOGY: Effects of teapolyphenol, EGCG (epigallocatechin-3-gallate) were studied. Proliferation of on human hepatoma cells, HLF, was measured with the use of WST-1 colorimetric assay. Cell invasion was analyzed by the Matrigel invasion assay. Morphology and immunohistological staining of expression of RAGE were also performed. RESULTS: Proliferation was inhibited with the addition of EGCG in a dose-dependent manner. EGCG (200 mumol/L) produced a profound growth suppression of HLF cells (24.5%). Cell invasion was also inhibited with preincubation of 100 mumol/L of EGCG (10.2%). In addition to the antitumor effects, neurite-like conformational changes of HLF cells were observed. Addition of EGCG (100 mumol/L) showed the expression of RAGE on cell surface in accordance to the morphological changes. CONCLUSIONS: The pathway associated to cell movement might be activated with RAGE expression. Although EGCG inhibits the growth and invasion, the cells which expressed RAGE seem to survive. Thus, the enrollment of RAGE should be analyzed to clarify the mechanisms of cancer resistance.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Carcinoma Hepatocelular/patologia , Catequina/análogos & derivados , Catequina/farmacologia , Neoplasias Hepáticas/patologia , Receptores Imunológicos/efeitos dos fármacos , Chá , Células Tumorais Cultivadas/patologia , Divisão Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Invasividade Neoplásica/patologia , Neuritos/efeitos dos fármacos , Neuritos/patologia , Receptor para Produtos Finais de Glicação Avançada
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA